I would think near zero chance of approval given that population size. With a quick turnaround on phase 3 protocol and trial start, possible results by the end of November.

With the longhauler patient advocates well aware of leronlimab the phase 3 should fill extremely fast. With a positive p value those advocates will be quite strident with the FDA for quick approval.